Order Article Reprints

Sanchez MV, Ebensen T, Schulze K, Cargnelutti DE, Scodeller EA, Guzmán CA. Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG. Pharmaceutics. 2023; 15(3):912. https://doi.org/10.3390/pharmaceutics15030912

Sanchez, Maria Victoria, Thomas Ebensen, Kai Schulze, Diego Esteban Cargnelutti, Eduardo A. Scodeller, and Carlos A. Guzmán. 2023. "Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG" Pharmaceutics 15, no. 3: 912. https://doi.org/10.3390/pharmaceutics15030912

Sanchez, M. V., Ebensen, T., Schulze, K., Cargnelutti, D. E., Scodeller, E. A., & Guzmán, C. A. (2023). Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG. Pharmaceutics, 15(3), 912. https://doi.org/10.3390/pharmaceutics15030912